Novo Nordisk Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Novo Nordisk wird ein jährliches Gewinn- und Umsatzwachstum von 14.4% bzw. 13.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 65% betragen.

Wichtige Informationen

14.4%

Wachstumsrate der Gewinne

15.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	13.3%
Zukünftige Eigenkapitalrendite	65.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

Gewinn- und Umsatzwachstumsprognosen

NYSE:NVO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (DKK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	406,381	149,387	118,162	163,905	22
12/31/2025	349,334	127,974	94,213	140,958	26
12/31/2024	290,128	101,959	74,396	122,755	26
6/30/2024	258,003	89,898	66,027	115,334	N/A
3/31/2024	244,243	89,276	50,304	93,408	N/A
12/31/2023	232,261	83,683	70,012	108,908	N/A
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	33,787	44,538	N/A
3/31/2018	110,174	38,725	N/A	38,885	N/A
12/31/2017	111,696	38,130	N/A	41,168	N/A
9/30/2017	113,276	38,576	N/A	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A
9/30/2013	82,836	24,886	N/A	22,084	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NVODas prognostizierte Gewinnwachstum (14.4% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: NVODie Erträge des Unternehmens (14.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: NVODie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: NVODie Einnahmen des Unternehmens (13.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: NVODie Einnahmen des Unternehmens (13.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NVODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (65%).

Novo Nordisk Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk: Better Buying Opportunities Ahead

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk: Buy On Dips

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Novo Nordisk: Considerable Growth Beyond Ozempic

The FTC Cracks Down On Novo Nordisk's Ozempic

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Novo Nordisk: The Moat Won't Last Forever

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Novo Nordisk, A Very Healthy Pharma Stalwart

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.